Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Ara R, Basarir H, Ward SE. Principles of health economic evaluations of lipid-lowering strategies. Curr Opin Lipidology. 2012 Aug;23(4):271-81. doi: 10.1097/MOL.0b013e32835423d9
Vitolins MZ, Anthony M, Burke GL. Soy protein isoflavones, lipids and arterial disease. Curr Opin Lipidology. 2001 Aug;12(4):433-7.
Williams VSL, Jones LV, Tukey JW. Controlling error in multiple comparisons, with examples from state-to-state differences in educational achievement. J Educ Behav Stat. 1999;24(1):42-69. doi: 10.3102/10769986024001042